Record #1 of 20
@article{Gao21,
author = {Gao, Y, Shi, S, Liu, M, Wu, F, Zhang, J, Song, F, and Tian, J},
title = {Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {10},
year = {2021},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide compared with platinum‐etoposide alone for the first‐line treatment of extensive‐stage small cell lung cancer (ES‐SCLC).},
DOI = {10.1002/14651858.CD014809},
URL = {http://dx.doi.org/10.1002/14651858.CD014809}
}


Record #2 of 20
@article{Gao22,
author = {Gao, Y, Liu, M, Li, L, Zhang, J, Song, F, and Tian, J},
title = {Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {9},
year = {2022},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the efficacy and safety of PD‐1 inhibitors or PD‐L1 inhibitors plus chemotherapy compared with chemotherapy for people with early triple‐negative breast cancer.},
DOI = {10.1002/14651858.CD015072},
URL = {http://dx.doi.org/10.1002/14651858.CD015072}
}


Record #3 of 20
@article{Kim23,
author = {Kim, S, Kang, TW, Cha, H, Kim, MH, Jung, JH, and You, SH},
title = {Consolidative thoracic radiotherapy for extensive disease small cell lung cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {8},
year = {2023},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of consolidative thoracic radiotherapy after chemotherapy in comparison with chemotherapy alone for ED SCLC.},
DOI = {10.1002/14651858.CD015567},
URL = {http://dx.doi.org/10.1002/14651858.CD015567}
}


Record #4 of 20
@article{Nishie21,
author = {Nishie, K, Yamamoto, S, Yamaga, T, Horita, N, Mori, R, Gouda, MA, and Hanaoka, M},
title = {Prophylactic cranial irradiation for extensive‐stage small cell lung cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {3},
year = {2021},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of PCI plus standard treatment compared to standard treatment alone in people with ED‐SCLC who have responded to first‐line chemotherapy.},
DOI = {10.1002/14651858.CD014559},
URL = {http://dx.doi.org/10.1002/14651858.CD014559}
}


Record #5 of 20
@article{Zhu19,
author = {Zhu, Z, Zhang, K, Cai, N, Charbek, E, Miller, AC, Zhu, S, Suo, C, Chen, X, and Song, H},
title = {Checkpoint inhibitors for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol},
journal = {Cochrane Database of Systematic Reviews},
number = {6},
year = {2019},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors in people with stage I to III NSCLC who receive surgery or radiotherapy with curative intent.},
DOI = {10.1002/14651858.CD013364},
URL = {http://dx.doi.org/10.1002/14651858.CD013364}
}


Record #6 of 20
@article{Marchal24,
author = {Marchal, C, Orillard, E, Calais, F, and Westeel, V},
title = {Immunotherapy for non‐small cell lung cancer in the elderly population: a generic protocol},
journal = {Cochrane Database of Systematic Reviews},
number = {7},
year = {2024},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (ICI) as monotherapy or in combination compared to standard of care for elderly people (≥ 65 years) with non‐small cell lung cancer (NSCLC).},
DOI = {10.1002/14651858.CD014907.pub2},
URL = {http://dx.doi.org/10.1002/14651858.CD014907.pub2}
}


Record #7 of 20
@article{Syn18,
author = {Syn, NLX, Roudi, R, Wang, LZ, Wang, L, Loh, M, Huang, Y, Ou, SHI, Soong, R, Drilon, A, and Wee, I},
title = {Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first‐line treatment of advanced non‐small cell lung cancer: a generic protocol},
journal = {Cochrane Database of Systematic Reviews},
number = {4},
year = {2018},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the effectiveness and toxicity of immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy alone as first‐line treatment of advanced non‐small cell lung cancer (NSCLC).},
DOI = {10.1002/14651858.CD013009},
URL = {http://dx.doi.org/10.1002/14651858.CD013009}
}


Record #8 of 20
@article{Haugaard24,
author = {Haugaard, AK, Saude Conde, R, J Maria, AR, Vithal Yergolkar, A, Jørgensen, KJ, and Heleno, B},
title = {Immunotherapy for advanced and recurrent malignant pleural mesothelioma},
journal = {Cochrane Database of Systematic Reviews},
number = {9},
year = {2024},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of immune checkpoint inhibitors (single‐agent or combination therapy) in people with advanced malignant pleural mesothelioma in a first‐line or salvage setting.},
DOI = {10.1002/14651858.CD014720},
URL = {http://dx.doi.org/10.1002/14651858.CD014720}
}


Record #9 of 20
@article{Van der Veen17,
author = {van der Veen, J, Laenen, A, and Nuyts, S},
title = {Modern radiotherapy techniques versus three‐dimensional conformal radiotherapy for head and neck cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {12},
year = {2017},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of modern radiotherapy techniques (IMRT, VMAT, proton beam therapy and adaptive radiotherapy) compared to 3DCRT on disease control and toxicity in head and neck cancer patients.},
DOI = {10.1002/14651858.CD012904},
URL = {http://dx.doi.org/10.1002/14651858.CD012904}
}


Record #10 of 20
@article{Chan23,
author = {Chan, WY, Sim, H-W, Abdi Haryono, M, Yip, D, and Chin, V},
title = {Immune checkpoint inhibitors for advanced pancreatic cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {2},
year = {2023},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of immune checkpoint inhibitors (ICIs), as monotherapy or in combination (with chemotherapy or targeted therapy), for people with advanced pancreatic cancer compared with chemotherapy, targeted therapy, or placebo.},
DOI = {10.1002/14651858.CD014523},
URL = {http://dx.doi.org/10.1002/14651858.CD014523}
}


Record #11 of 20
@article{Soon18,
author = {Soon, YY, Zheng, Q, Shi, L, Chan, ESY, Leong, CN, Koh, WY, and Tham, IWK},
title = {Chemo‐radiotherapy versus surgery‐based treatment for Stage IIIA non‐small cell lung cancer: a systematic review and network meta‐analysis},
journal = {Cochrane Database of Systematic Reviews},
number = {4},
year = {2018},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effectiveness and safety of chemo‐radiotherapy with surgery for people with Stage IIIA non‐small cell lung cancer (NSCLC).},
DOI = {10.1002/14651858.CD012999},
URL = {http://dx.doi.org/10.1002/14651858.CD012999}
}


Record #12 of 20
@article{Moraes17,
author = {Moraes, FY, Perry, LA, Penny‐Dimri, JC, Ramson, D, de Castria, TB, Bowman, RV, Santos, FN, Fong, KM, and Riera, R},
title = {Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) versus chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {4},
year = {2017},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer (NSCLC).},
DOI = {10.1002/14651858.CD012644},
URL = {http://dx.doi.org/10.1002/14651858.CD012644}
}


Record #13 of 20
@article{Madrid18,
author = {Madrid, E, Barros Monge, MJ, Urrútia, G, Roqué i Figuls, M, Pérez Bracchiglione, J, Vargas Peirano, M, Loézar Hernández, CN, and Bonfill Cosp, X},
title = {Taxanes for advanced non‐small cell lung cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {7},
year = {2018},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of taxanes as part of a combined or single‐agent therapy versus other agents or best supportive care as first‐ or second‐line treatment for advanced non‐small cell lung cancer (NSCLC). A secondary objective is to assess different modes or schemes of administration of taxanes in patients with this disease.},
DOI = {10.1002/14651858.CD013075},
URL = {http://dx.doi.org/10.1002/14651858.CD013075}
}


Record #14 of 20
@article{Zhao22,
author = {Zhao, Y, Feng, H-m, Tian, J, Li, B, Wang, C, Ge, L, Feng, S-f, and Yu, Q},
title = {Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non‐small cell lung cancer: a systematic review and network meta‐analysis},
journal = {Cochrane Database of Systematic Reviews},
number = {4},
year = {2022},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and toxicity of different SBRT schedules (± additional treatments) in comparison with various more fractionated radical radiotherapy schedules (± additional treatments) in controlling primary tumor and prolonging survival in people with early stage NSCLC, and to rank all the schedules based on their efficacy and tolerability. },
DOI = {10.1002/14651858.CD014744},
URL = {http://dx.doi.org/10.1002/14651858.CD014744}
}


Record #15 of 20
@article{Liu23,
author = {Liu, L, Wang, T, Chen, Y, and Cao, Y},
title = {Electronic symptom monitoring for patients with advanced cancer},
journal = {Cochrane Database of Systematic Reviews},
number = {7},
year = {2023},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of electronic symptom monitoring (ESM) on patient survival, hospital admission, emergency visit, changes in treatment protocol, adverse events, patient‐reported outcomes (PROs), and cost‐effectiveness for patients with advanced cancer.},
DOI = {10.1002/14651858.CD015732},
URL = {http://dx.doi.org/10.1002/14651858.CD015732}
}


Record #16 of 20
@article{Galvão20,
author = {Galvão, TF, Livinalli, A, Lopes, LC, Zimmermann, IR, and Silva, MT},
title = {Biosimilar monoclonal antibodies for cancer treatment},
journal = {Cochrane Database of Systematic Reviews},
number = {2},
year = {2020},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy, effectiveness, and safety of biosimilar monoclonal antibodies for treating cancer, when compared to their originator biologic.},
DOI = {10.1002/14651858.CD013539},
URL = {http://dx.doi.org/10.1002/14651858.CD013539}
}


Record #17 of 20
@article{Ma24,
author = {Ma, M, Yao, L, Li, M, Qin, Y, Yang, M, Guo, K, Duan, Y, Liu, B, and Yang, K},
title = {Granulopoiesis‐stimulating factors to prevent adverse effects in the treatment of solid tumors},
journal = {Cochrane Database of Systematic Reviews},
number = {1},
year = {2024},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the efficacy of prophylactic granulopoiesis‐stimulating factors compared with placebo or no prophylaxis for improving survival and preventing adverse effects of cancer treatment in people with solid tumors.},
DOI = {10.1002/14651858.CD015656},
URL = {http://dx.doi.org/10.1002/14651858.CD015656}
}


Record #18 of 20
@article{Williams18,
author = {Williams, M, Chen, J, Hart, MG, Hunter, A, Hawkins, N, Si, S, and Toni, F},
title = {First‐line treatments for people with single or multiple brain metastases},
journal = {Cochrane Database of Systematic Reviews},
number = {12},
year = {2018},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To compare the safety and efficacy of surgery, radiotherapy, and chemotherapy as first‐line treatment for people with single or multiple brain metastases, either alone or in combination.},
DOI = {10.1002/14651858.CD013223},
URL = {http://dx.doi.org/10.1002/14651858.CD013223}
}


Record #19 of 20
@article{Abdel‐Rahman19,
author = {Abdel‐Rahman, O, and Elsayed, Z},
title = {Immune checkpoint inhibitors for unresectable hepatocellular carcinoma},
journal = {Cochrane Database of Systematic Reviews},
number = {9},
year = {2019},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of immune checkpoint inhibitors versus placebo, no treatment, or other systemic or locoregional therapies for people with unresectable hepatocellular carcinoma.},
DOI = {10.1002/14651858.CD013431},
URL = {http://dx.doi.org/10.1002/14651858.CD013431}
}


Record #20 of 20
@article{Thielecke21,
author = {Thielecke, L, Stocker, LD, Florou, V, Monsef, I, Skoetz, N, and Herling, M},
title = {The role of high‐dose chemotherapy with autologous stem cell transplantation in adults with mature T‐cell lymphomas},
journal = {Cochrane Database of Systematic Reviews},
number = {9},
year = {2021},
publisher = {John Wiley & Sons, Ltd},
ISSN = {1465-1858},
abstract = {Abstract - Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To define the role of HDT followed by autoSCT in the treatment of MTCL in adults (≥18 years of age), particularly with respect to its efficacy and safety as a first‐line therapy, and secondarily for its efficacy and safety as a salvage option.},
DOI = {10.1002/14651858.CD014671},
URL = {http://dx.doi.org/10.1002/14651858.CD014671}
}


